Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress

EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the executive management team will webcast a review of Gritstone's clinical programs, including preliminary immunogenicity and safety data from its ongoing Phase 1 GRANITE and Phase 1 SLATE clinical trials following an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress. The investor call will be held on Thursday, December 12, 2019 at 8:00 am ET / 2:00 pm CET in Geneva, Switzerland.

The conference call can be accessed by dialing (866) 866-1333 or (404) 260-1421 and referencing conference ID number 49260042. A webcast of the call and accompanying slides will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology
Gritstone Oncology GRTS, a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy in Phase 1 clinical testing. Gritstone's second product candidate, SLATE, is a shared neoantigen, "off-the-shelf" immunotherapy which is also being evaluated in a Phase 1 clinical study. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com